FDA Approves First-Ever Treatment for Severe Frostbite

Aurlumyn aims to significantly reduce the risk of amputation for frostbite patients.

The U.S. Food and Drug Administration (FDA) has approved Aurlumyn, the first-ever treatment for severe frostbite in adults, aimed at reducing the risk of finger or toe amputation.
Aurlumyn, also known as iloprost, is an injectable vasodilator that opens blood vessels and prevents blood clots, initially approved in 2004 for pulmonary arterial hypertension.
In a controlled trial, Aurlumyn demonstrated a significant reduction in the need for amputation among severe frostbite patients compared to other treatments.
Common side effects of Aurlumyn include headache, flushing, heart palpitations, fast heart rate, nausea, vomiting, dizziness, and hypotension.
Experts emphasize the importance of frostbite prevention through proper clothing, equipment, and training for cold-weather activities.